EIC Summit 25 Networking Platform

2–3 Apr 2025 | Brussels, Belgium

VectorB2B

Incubators and Accelerators

vectorb2b.com/Lisbon, Portugal
2 profile visits

About

VectorB2B-Drug Developing is a non-profit association established in 2019, providing high-quality drug discovery and development services from bench to bedside. We offer not only standard assays but also high-value project design and innovative R&D solutions. Acting as both a solution provider and enabler, we deliver unique assays not typically found in conventional CROs or CMOs. This is made possible by leveraging knowledge and R&D from leading academic and biotech groups at the forefront of biological drug/target discovery, development, and evaluation. VectorB2B serves as a one-stop shop for companies and academia involved in biological drug discovery and development. Our expertise spans across Discovery, Toxicology, CMC, and CRO services, supporting health product development from design, lead selection, and optimization to production, characterization, formulation, and pre-clinical studies.

Social media

Objectives

Building consortiaOther

Topics

Agriculture & FoodHealth BiotechnologyMedical Technologies

Representatives

Ana Custódio

Co-CEO

VectorB2B

Marketplace (3)

  • Service

    EIC ACCESS+ Funded GLP Tox Services

    Regulatory toxicology studies in compliance with GLP, supporting drug, device, and chemical product development for regulatory submission.

    • Development
    Author

    Ana Custódio

    Co-CEO at VectorB2B

    Lisboa, Portugal

  • Service

    EIC Access + Funded CRO Services

    CRO solutions for drug development, from discovery to clinical trials, offering study design, data management, and regulatory support.

    • Development
    Author

    Ana Custódio

    Co-CEO at VectorB2B

    Lisboa, Portugal